| Attention deficit hyperactivity disorder
Azstarys vs Jornay PM
Side-by-side clinical, coverage, and cost comparison for attention deficit hyperactivity disorder.Deep comparison between: Azstarys vs Jornay Pm with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsJornay Pm has a higher rate of injection site reactions vs Azstarys based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Jornay Pm but not Azstarys, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Azstarys
Jornay Pm
At A Glance
Oral
Daily
CNS stimulant
Oral
Daily
CNS stimulant
Indications
- Attention deficit hyperactivity disorder
- Attention deficit hyperactivity disorder
Dosing
Attention deficit hyperactivity disorder (ages 6-12) Starting dose 39.2 mg/7.8 mg orally once daily in the morning; may increase to 52.3 mg/10.4 mg or decrease to 26.1 mg/5.2 mg after one week; maximum 52.3 mg/10.4 mg once daily.
Attention deficit hyperactivity disorder (ages 13-17 and adults) Starting dose 39.2 mg/7.8 mg orally once daily in the morning; increase after one week to 52.3 mg/10.4 mg once daily depending on response and tolerability; maximum 52.3 mg/10.4 mg once daily.
Attention deficit hyperactivity disorder 20 mg once daily orally in the evening (between 6:30 p.m. and 9:30 p.m.) as the starting dose for patients 6 years and older; titrate weekly in increments of 20 mg up to a maximum of 100 mg/day.
Contraindications
- Known hypersensitivity to serdexmethylphenidate, methylphenidate, or other components of AZSTARYS
- Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of MAOI treatment
- History of hypersensitivity to methylphenidate or other components of JORNAY PM
- Concomitant treatment with monoamine oxidase (MAO) inhibitors, or within 14 days following discontinuation of an MAO inhibitor
Adverse Reactions
Most common (>=5%) Decreased appetite, decreased weight, nausea, abdominal pain, dyspepsia, vomiting, insomnia, anxiety, affect lability, irritability, dizziness, increased blood pressure, tachycardia
Postmarketing Pancytopenia, thrombocytopenia, angina pectoris, bradycardia, supraventricular tachycardia, hepatocellular injury, acute hepatic failure, angioedema, anaphylactic reactions, urticaria, convulsion, serotonin syndrome, dyskinesia, hallucination, mania, rhabdomyolysis, priapism, Raynaud's phenomenon, alopecia
Most common (>=5%) Any insomnia, decreased appetite, headache, vomiting, nausea, psychomotor hyperactivity, affect lability or mood swings
Serious Hypersensitivity reactions (angioedema, anaphylaxis), hypertensive crisis with MAO inhibitors, serious cardiac events, psychiatric adverse reactions, priapism, peripheral vasculopathy including Raynaud's phenomenon, long-term suppression of growth in pediatric patients
Postmarketing Pancytopenia, thrombocytopenia, angina pectoris, bradycardia, severe hepatic injury, rhabdomyolysis, convulsion, serotonin syndrome, hallucinations, mania, priapism, alopecia, Raynaud's phenomenon
Pharmacology
CNS stimulant prodrug combination; serdexmethylphenidate is a prodrug of dexmethylphenidate, which blocks reuptake of norepinephrine and dopamine into the presynaptic neuron and increases release of these monoamines into the extraneuronal space.
CNS stimulant; methylphenidate is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space, though the exact mode of therapeutic action in ADHD is not known.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Azstarys
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
Jornay Pm
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (1/12)
UnitedHealthcare
Azstarys
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (4/8) · Qty limit (5/8)
Jornay Pm
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Azstarys
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Jornay Pm
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Azstarys.
No savings programs available for Jornay Pm.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AzstarysView full Azstarys profile
Jornay PmView full Jornay Pm profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.